



## Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences

November 4, 2025

WATERTOWN, Mass.--(BUSINESS WIRE)--Nov. 4, 2025-- [Enanta Pharmaceuticals, Inc.](#) (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in the following investor conferences in November and December.

- **Jefferies London Global Healthcare Conference:** Fireside Chat on Tuesday, November 18, 2025 at 1:00 p.m. GMT / 8:00 a.m. ET
- **8<sup>th</sup> Annual Evercore Healthcare Conference:** Fireside Chat on Wednesday, December 3, 2025 at 8:20 a.m. ET

A live webcast of each event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at [www.enanta.com](http://www.enanta.com). A replay of the webcasts will be available following the presentation and will be archived for at least 30 days.

### About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET<sup>®</sup> (U.S.) and MAVIRET<sup>®</sup> (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20251104405023/en/): <https://www.businesswire.com/news/home/20251104405023/en/>

### Media and Investors Contact

Jennifer Viera  
617-744-3848  
[jviera@enanta.com](mailto:jviera@enanta.com)

Source: Enanta Pharmaceuticals, Inc.